Stock Monitor: HEICO Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on Elbit Systems Ltd (NASDAQ: ESLT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ESLT . On December 19, 2017, the Company announced that it has been awarded a $46 million contract for the supply of J-Music™ DIRCM (Direct Infrared Countermeasures) self-protection systems to NATO. This is a follow-on contract valued $46 million. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for HEICO Corporation (NYSE: HEI), which also belongs to the Industrial Goods sector as the Company Elbit Systems. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=HEI

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Elbit Systems most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ESLT

The contract envisions that Elbit Systems provide additional J-Music™ DIRCM self-protection systems for NATO’s Airbus A330 Multinational Multi-Role Tanker Transport Fleet (MMF) Program. The contract is for the duration of four years. Under the contract, Elbit Systems will equip NATO’s Airbus A330 tankers with the J-Music™ DIRCM systems along with the Company’s Infra-Red-based Passive Airborne Warning Systems (PAWS IR).

Management Comments

Commenting on being awarded the NATO contract, Elad Aharonson, General Manager of Elbit Systems ISTAR Division, said:

“This follow-on contract that extends the supply of J-Music DIRCM and PAWS IR missile warning systems to NATO’s MMF program, attests to Elbit Systems’ technological and operational competitive advantage in addressing the intensifying threat of shoulder-launched surface-to-air missiles.”

Colonel Jan der Kinderen, Chairman of the MMF Steering Group, added:

“The MMF users are very pleased that the Multi Role Tanker Transport aircraft (MRTTs) are going to be equipped with Elbit Systems’ J-Music DIRCM system. This will greatly add to the safety and operational flexibility of the total fleet. It is also great to see how Airbus and Elbit Systems work closely together to integrate the systems.”

Peter DOHMEN, General Manager, NATO Support and Procurement Agency (NSPA), commented:

“NSPA is pleased to award this contract to Elbit Systems and provide an important capability for NATO’s A330 tanker fleet, which will allow the aircraft, crew, and passengers to operate more safely in hostile environments.”

About Elbit Systems’ J-Music™ DIRCM

J-MUSIC™ is one of Elbit Systems’ Airborne Self-Protection and Payload Systems. It is a market leading Direct Infra-Red Counter Measures (DIRCM) system, optimized to protect jet aircraft from shoulder-fired missiles (MANPADS). The highly advanced and fully proven J-MUSIC™ system is designed for distributed installation on a variety of aircraft types, in a single or multi-turret configuration. The key features of the system are that it is light-weight, compact, and easily installed on a broad range of aircraft types. The system has an open architecture which allows integration of the system with various Missile Warning Systems (MWS). This makes it one of the most comprehensive and markets’ leading protection systems in the civil and military market. The Company has provided these systems to the German Air Force as well as private aircraft owners.

About Elbit Systems Ltd

Haifa, Israel-based Elbit Systems is an international high technology Company engaged in a wide range of defense, homeland security, and commercial programs. The Company and its subsidiaries offer a wide range of aerospace, land, and naval systems which include command, control, communications, computers, intelligence surveillance, and reconnaissance (“C4ISR”), unmanned aircraft systems, advanced electro-optics, electro-optic space systems, EW suites, signal intelligence systems, data links and communications systems, and radios and cyber-based systems. The Company also provides a range of additional support services, including training and simulation systems.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, Elbit Systems’ stock rose 2.21%, ending the trading session at $134.50.

Volume traded for the day: 57.90 thousand shares, which was above the 3-month average volume of 34.23 thousand shares.

Stock performance in the last six-month period – up 7.63%; past twelve-month period – up 34.07%; and year-to-date – up 32.01%

After yesterday’s close, Elbit Systems’ market cap was at $5.72 billion.

Price to Earnings (P/E) ratio was at 24.28.

The stock has a dividend yield of 1.31%.

The stock is part of the Industrial Goods sector, categorized under the Aerospace/Defense Products & Services industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484756

Stock Monitor: DLH Holdings Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on Engility Holdings, Inc. (NYSE: EGL). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EGL. On December 19, 2017, the Company announced that it has been selected as the approved vendor for the Alliant 2 government-wide acquisition contract (GWAC) with the US General Services Administration (GSA). Under the Alliant 2, Engility will provide customized IT services and solutions. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for DLH Holdings Corp. (NASDAQ: DLHC), which also belongs to the Services sector as the Company Engility Holdings. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=DLHC

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Engility Holdings most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=EGL

Commenting on being a part of Alliant 2, Luis Almodovar, Vice President of GWAC and IDIQ (indefinite delivery, indefinite quantity) Solutions at Engility, said:

“Alliant 2 enhances our ability to bid on and win critical work around the globe. The Office of Management and Budget named Alliant 2 as best in class for IT solutions, and we are excited to be among the Companies chosen to participate, continuing relationships we built under the Alliant Program.”

Scope of Alliant 2 GWAC

As per the terms of the Alliant 2 GWAC, Engility will provide key IT services and solutions including systems engineering and integration, cyber, high performance computing and enterprise solutions. These services and solutions are expected to support the IT systems and modernization efforts of the Federal Government. The Company will provide the complete IT solutions and services which will be customized as per the requirements of GSA. The Alliant 2 GWAC is initially for a 5-year term with a provision to extend it for an additional 5 years.

The Company believes that it was awarded this contract based on its capabilities in high-demand areas viz. cybersecurity, cloud computing, artificial intelligence, big data, biometrics, Internet of Things, and virtual networking. The bagging of the contract is expected to boost the Company’s IDIQ portfolio and allow it to get more orders.

About Alliant 2 GWAC

A GWAC is a pre-competed, multiple-award, IDIQ contract that agencies can use to buy total IT solutions. The Alliant 2 GWAC is a similar contract from GSA for providing customized Information Technology (IT) services and IT services-based solutions. The Alliant 2 has a $50 billion ceiling and is available for use by all Federal agencies and other entities. In November 2017, GSA announced the list of 61 companies which were awarded contracts under Alliant 2. These companies have already earned “best-in-class” status from the Office of Management and Budget. The Alliant 2 allows federal agencies to access integrated information technology (IT) solutions for evolving needs on a global basis and the ability to stay on the forefront of emerging IT services.

Alliant 2 is the second version of GSA’s successful Alliant GWAC and has been enhanced to include scope improvements, new IT service labor categories, new cybersecurity standards, and new environmental standards. The Alliant 2 also incorporates the Defense Federal Acquisition Regulation Supplement (DFARS) regulations/provisions into the master contract so that the contract awardees can automatically flow down to the task order level on any/all task orders issued by a Department of Defense (DoD) agency. Since the contracts awarded under Alliant GWAC expire in April 2019, the Alliant 2 provides federal clients, with long-term task order requirements exceeding five years, to consider the Alliant 2 GWACs.

About Engility Holdings, Inc.

Chantilly, Virginia based Engility is a premier provider of integrated solutions and services to the US government customers in the defense, federal civilian, intelligence, and space communities. The Company’s solutions and services include an array of specialized technical service offerings include high-performance computing, cybersecurity, enterprise modernization, and systems engineering. The Company is known for providing world-class solutions and services, balanced performance, efficiency, and best value. The Company’s intimate understanding of customers’ needs, deep domain expertise, and the team of skilled professionals allows it to develop and deliver on-target solutions for critical missions. The Company has operations spread across 50 countries and is supported by a team of approximately 8,800 employees. In FY16, the Company’s revenues were $2.1 billion.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, Engility Holdings’ stock climbed 4.13%, ending the trading session at $28.77.

Volume traded for the day: 114.64 thousand shares.

Stock performance in the last month – up 1.84%; and previous six-month period – up 6.12%

After yesterday’s close, Engility Holdings’ market cap was at $1.06 billion.

Price to Earnings (P/E) ratio was at 34.54.

The stock is part of the Services sector, categorized under the Staffing & Outsourcing Services industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484757

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on Jack in the Box Inc. (NASDAQ: JACK). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JACK. On December 19, 2017, the Company announced that it has signed an agreement to sell off its wholly owned subsidiary – Qdoba Restaurant Corporation to certain funds managed by affiliates of Apollo Global Management, LLC (NYSE: APO) (“Apollo”). The all-cash deal is valued approximately $305 million and is subject to adjustments at the time of closing of the transaction. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Jack in the Box most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=JACK

www.active-investors.com/registration-sg/?symbol=APO

The transaction is expected to close by April 2018 and is subject to regulatory approvals and other closing conditions. Jack in the Box plans to utilize the funds raised from this sale to retire its long-term credit facility.

With this acquisition, Apollo is expanding its portfolio of food-related businesses. Apollo already owns specialty grocery retailer The Fresh Market (acquired in 2016) and Chuck E. Cheese’s parent CEC Entertainment, Inc. (acquired in 2014). Apollo also owns stock in Hostess Brands, Inc.

Commenting on the sale of Qdoba, Lenny Comma, Chairman and CEO of Jack in the Box, said:

“For the past several months, we have worked closely with our financial advisors and evaluated various strategic alternatives with respect to Qdoba, including a sale or spin-off as well as opportunities to refranchise Company restaurants. Following the completion of this robust process, our Board of Directors has determined that the sale of Qdoba is the best alternative for enhancing shareholder value and is consistent with the Company’s desire to transition to a less capital-intensive business model.”

Lance Milken, Senior Partner at Apollo, added:

“We are extremely excited to be acquiring Qdoba and look forward to working with the management team, employees and franchisees to continue building the Qdoba brand. We are firmly committed to Qdoba’s continued growth as a leading fast-casual restaurant operator.”

About Qdoba

Qdoba Mexican Eats is the brand under which Qdoba Restaurant Corporation owned and operated a chain of fast casual restaurants serving Mexican-style food. Qdoba was founded in 1995 and was acquired by Jack in the Box in January 2003 for $45 million. At the time of acquisition in 2003, Qdoba had 85 restaurant locations in 16 states in the US and annual sales of $65 million. At present, there are over 700 restaurant locations in 48 states in US as well as in Canada. Qdoba also provides catering services. Qdoba’s sales for the fiscal year 2017 was over $820 million.

Qdoba’s same-store sales have been declining in recent times and was affecting the overall performance and valuations of Jack in the Box. Some of the leading factors influencing the decline of Qdoba’s business included rising labor costs, increased competition in the fast-casual dining sector, and sudden jump in avocado prices. Hence, Jack in the Box had been contemplating strategic alternatives for Qdoba since the start of this year.

Consolidation in the Restaurants business

The Restaurant business has been witnessing a trend of consolidation as evidenced by some of the recent deals. In November 2017, Private-equity firm Roark Capital, the parent Company of Arby’s Restaurant Group, announced the acquisition of Buffalo Wild Wings for approximately $2.9 billion. In October 2017, Atlanta-based private equity firm NRD Capital acquired Restaurant Chain Ruby Tuesday for an enterprise value of about $335 million. In May 2017 private-equity firm Golden Gate Capital completed the acquisition of Bob Evans Restaurants in a $565 million-plus deal. In February 2017, Restaurant Brands International Inc. (owners of Burger King®) announced the acquisition of Popeyes Louisiana Kitchen, Inc., a chicken-focused fast-food chain, in a deal valued at $1.8 billion.

About Jack in the Box Inc.

Founded in 1951, San Diego, California based Jack in the Box is a leading fast-food hamburger chains that operates and franchises Jack in the Box® restaurants. It has more than 2,200 quick-serve restaurants in 21 states and Guam. It offers a selection of distinctive, innovative products including hamburgers, specialty sandwiches, salads, and real ice cream shakes. It is supported by a team of over 20,000 employees.

About Apollo Global Management LLC

Founded in 1990, Apollo is an alternative investment manager in private equity, credit, and real estate. The Company has total asset under management (AUM) of approximately $242 billion as of September 30, 2017. Apollo focuses on opportunities in nine core industries including Business Services, Chemicals, Consumer Services, Consumer & Retail, Financial Services, Leisure, Manufacturing & Industrial, Media/Telecom/Technology and Natural Resources. It has offices across the globe including in New York, Los Angeles, Houston, Chicago, St. Louis, Bethesda, Toronto, London, Frankfurt, Madrid, Luxembourg, Mumbai, Delhi, Singapore, Hong Kong and Shanghai. The investment firm has a team of 988 employees, including 368 investment professionals.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, Jack in the Box’s stock fell 3.16%, ending the trading session at $100.18.

Volume traded for the day: 1.09 million shares, which was above the 3-month average volume of 675.58 thousand shares.

Stock performance in the last three-month period – up 2.92%

After yesterday’s close, Jack in the Box’s market cap was at $2.96 billion.

Price to Earnings (P/E) ratio was at 22.31.

The stock has a dividend yield of 1.60%.

The stock is part of the Services sector, categorized under the Restaurants industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484758

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free earnings report on Zynga Inc. (NASDAQ: ZNGA). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZNGA . The Company posted its financial results on November 07, 2017, for the third quarter of the fiscal year 2017. The San Francisco, California-based Company’s revenues rose 23% y-o-y, while its booking grew 9% during the reported quarter. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Zynga most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ZNGA

Earnings Highlights and Summary

During Q3 FY17, Zynga reported total revenues of $224.60 million, which came in above the $182.42 million recorded at the end of Q3 FY16. The Company’s quarterly total revenue numbers topped Wall Street’s expectations of $209.8 million. Furthermore, online game revenue rose to $175.25 million in Q3 FY17 from $134.25 million in Q3 FY16. The Company’s advertising and other revenues grew to $49.34 million in Q3 FY17 from $48.17 million in Q3 FY16.

The developer of ‘FarmVille’ and other online games reported a net income of $18.09 million, or $0.02 per diluted common share, in Q3 FY17 versus a net loss of $41.74 million, or $0.05 per diluted common share, in the prior year’s same quarter; The reported earnings per share (EPS) was in-line with market analysts’ expectations of $0.02 per diluted share.

Operating Metrics

For Q3 FY17, Zynga’s cost of revenue was $65.91 million compared to $62.68 million in Q3 FY16. The Company spent $60.97 million on research and development (R&D) in Q3 FY17, lower than the $73.91 million recorded in Q3 FY16. The Company’s sales and marketing (S&M) costs increased to $53.94 million in Q3 FY17 from $49.80 million in Q3 FY16. Furthermore, Zynga’s general and administrative (G&A) expenses were $23.83 million in Q3 FY17 versus $21.66 million in the last year’s comparable quarter.

Zynga reported income from operations of $19.95 million in Q3 FY17 versus a loss from operations of $46.30 million in the year ago corresponding quarter. Moreover, the Company’s adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) came in at $44.59 million for the reported quarter compared to $3.58 million in Q3 FY16.

Segment Performance

During Q3 FY17, Zynga’s Mobile segment’s revenues came in at $194.39 million, up 33% from $145.91 million in the previous year’s same quarter. Mobile bookings were $186.54 million during Q3 FY17, up 15% from $162.32 million in Q3 FY16. Moreover, average mobile DAUs grew 19% to 19 million y-o-y in Q3 FY17.

The Company’s Advertising segment’s revenues were $46.35 million for the reported quarter compared to $47.00 million in Q3 FY16. Advertising bookings were $45.58 million during Q3 FY17 versus $48.59 million in Q3 FY16.

Cash Flow and Balance Sheet

During the three months ended September 30, 2017, Zynga generated $35.09 million of cash from operations versus $21.03 million in the previous year’s comparable period. Free cash flow increased to $32.35 million in Q3 FY17 from $18.36 million in Q3 FY16. Furthermore, the Company had cash and cash equivalents of $517.26 million as on September 30, 2017, versus $852.47 million as on December 31, 2016.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, Zynga’s stock slightly dropped 0.25%, ending the trading session at $3.96.

Volume traded for the day: 4.47 million shares.

Stock performance in the last three-month – up 2.33%; previous six-month period – up 9.39%; past twelve-month period – up 47.21%; and year-to-date – up 54.09%

After yesterday’s close, Zynga’s market cap was at $3.41 billion.

The stock is part of the Technology sector, categorized under the Multimedia & Graphics Software industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484752

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on AerCap Holdings N.V. (NYSE: AER) (“AerCap”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AER. On December 19, 2017, the Company declared that it has struck an agreement with Peregrine Aviation Co. Ltd (“Peregrine Aviation”) to sell a 21-aircraft portfolio valued at $800 million. The portfolio consists of a mix of wide-body and narrow-body aircraft on lease to 14 airlines across the world. Peregrine Aviation is an investment entity established by NCB Capital, the brokerage arm of the National Commercial Bank. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, AerCap Holdings most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AER

Agreement Details

The acquisition of the portfolio is part-financed with a non-recourse term loan arranged by BNP Paribas, Citibank, and Credit Suisse. Under the agreement, AerCap will provide technical and lease management services to Peregrine Aviation and will also retain an equity interest in the entity. Milbank, Tweed, Hadley & McCloy LLP served as legal advisors to both Companies.

With the Sale, AerCap Will Have Sold, or Contracted to Sell, $2.4 Billion of Mid-Life Assets in 2017

Commenting on the agreement, Aengus Kelly, Chief Executive Officer (CEO) of AerCap, mentioned that with this sale, AerCap will have sold, or contracted to sell, approximately $2.4 billion of mid-life assets in 2017. The transaction is further evidence of the reach of AerCap’s platform and its disciplined approach to portfolio management.

AerCap’s Leased, Purchased, and Sold Portfolio in Q3 2017

On October 05, 2017, the Company announced that in Q3 2017, it has signed lease agreements for 50 aircraft, including 17 wide-body aircraft and 33 narrow body aircraft, of which 8 are Embraer E2-Jet Family aircraft. AerCap purchased 11 aircraft, including 2 Airbus A320neo Family aircraft, 1 Airbus A350, and 8 Boeing 787s. The Company has signed financing transactions for $3.7 billion in Q3 2017.

In Q2 2017, AerCap signed lease agreements for 65 aircraft, including 18 wide body and 47 narrow body aircraft, and purchased 11 aircraft, including 8 Airbus A320neos, 1 Airbus A321neo, and 2 Boeing 787-9s. In the same quarter, the Company executed sale transactions for 32 aircraft and signed an agreement with Boeing for an order of 30 787-9 aircraft.

AerCap Sold $0.6 Billion Aircraft Portfolio in 2015

In September 2015, the Company completed the sale of a 10-aircraft portfolio to an entity advised by Magnetar Capital. The aircraft types included four A330-200s, two 777-200ERs, two 777-300ERs, and two A320-200s, with an average age of approximately 10.5 years. As part of the sale, AerCap entered into an agreement with the purchaser under which it continued to service the portfolio.

About AerCap Holdings N.V.

Founded in 1995, AerCap is the global leader in aircraft leasing and aviation finance. The Company’s high quality and well-diversified portfolio of aircraft, one of the largest in the world, provides a global network of airline customers with comprehensive fleet solutions. AerCap is headquartered in Dublin, Ireland, with offices in Amsterdam, Los Angeles, Shannon, Fort Lauderdale, Singapore, Shanghai, Abu Dhabi, Seattle, and Toulouse.

About NCB Capital

Established in 2007, NCB Capital is the investment banking and asset management arm of the National Commercial Bank (over 90% ownership), providing clients with premier solutions of integrated investment services. NCB Capital is the largest Asset Manager in the Kingdom of Saudi Arabia, and the largest Sharia-compliant Asset Manager globally with over SAR140 billion of assets under management.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, AerCap Holdings’ stock slightly declined 0.09%, ending the trading session at $52.69.

Volume traded for the day: 875.02 thousand shares.

Stock performance in the last month – up 3.58%; previous three-month period – up 5.04%; past twelve-month period – up 23.63%; and year-to-date – up 26.63%

After yesterday’s close, AerCap Holdings’ market cap was at $8.24 billion.

Price to Earnings (P/E) ratio was at 7.79.

The stock is part of the Services sector, categorized under the Air Services, Other industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484753

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on Amphastar Pharma, Inc. (NASDAQ: AMPH). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AMPH. On December 19, 2017, the specialty pharmaceutical Company that mainly focuses on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable and inhalation products, declared that the US Food and Drug Administration has granted approval of its abbreviated new drug application (ANDA) for Sodium Nitroprusside Injection 25mg/mL, 2mL single dose vial. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Amphastar Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AMPH

Usage of the Sodium Nitroprusside Injection

The Sodium Nitroprusside Injection has been indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crisis. It has also been designated for producing controlled hypotension in order to reduce bleeding during surgery as well as for the treatment of acute congestive heart failure.

The FDA has suggested that this newly approved product of Amphastar is therapeutically equivalent to Nitropress® (i.e. Sodium Nitroprusside Injection) sold in the United States by Valeant Pharmaceuticals.

Amphastar plans to launch the Sodium Nitroprusside Injection in the first quarter of 2018.

Implications for Amphastar

The approval of Amphastar’s Sodium Nitroprusside Injection would expand the Company’s product offerings in the generic injectable portfolio. Besides, it would also strengthen its vertical integration strategy, as the Active Pharmaceutical Ingredient in this product is being manufactured by ANP, Amphastar’s Chinese subsidiary.

As per recent IQVIA data, the US brand and generic sales of Sodium Nitroprusside Injection, 25 mg/mL, 2mL vials were approximately $73.8 million for the 12 months ending September 30, 2017.

Amphastar’s Robust Product Pipeline

At present, Amphastar has three abbreviated new drug applications, or ANDAs filed with the FDA, three biosimilars products and 11 generic products in development.

These products have significant market value. For instance, the three new ANDAs target products with a market size of more than $0.5 billion. The biosimilars products comprise products with a market size of $15.0 billion, while the generic products target a market of over $12.0 billion. This market information is based on the IQVIA data for the 12 months ending September 30, 2017.

Besides, Amphastar’s proprietary pipeline also includes NDAs for Primatene® Mist and intranasal naloxone.

Approval of Medroxyprogesterone Acetate Injectable Suspension

Another important development for Amphastar is that, on November 29, 2017, FDA granted approval for two of its abbreviated new drug applications for Medroxyprogesterone Acetate Injectable Suspension, USP, 150 mg/mL, 1mL vial, and 1mL prefilled syringe, respectively, indicated for the prevention of pregnancy. The Company intends to launch this product in the first quarter of 2018.

As per IMS Health, US brand and authorized generic sales of Medroxyprogesterone Acetate Injectable Suspension, USP, 150 mg/mL, 1mL vials, and 1mL prefilled syringes were around $316 million for the 12 months ending September 30, 2017.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, Amphastar Pharma’s stock marginally climbed 0.68%, ending the trading session at $19.31.

Volume traded for the day: 214.74 thousand shares.

Stock performance in the last month – up 5.35%; previous three-month period – up 17.74%; past six-month period – up 9.41%; and year-to-date – up 4.83%

After yesterday’s close, Amphastar Pharma’s market cap was at $861.61 million.

Price to Earnings (P/E) ratio was at 4827.50.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers-Other industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484754

Stock Monitor: Stellar Biotechnologies Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on Asterias Biotherapeutics, Inc. (NYSE: AST) (“Asterias”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AST. On December 19, 2017, the Company announced the enrollment and dosing of the last subject in its SciStar Phase-1/2a clinical study of AST-OPC1 in motor complete cervical spinal cord injury (SCI). Asterias, a biotechnology Company specializing in the field of regenerative medicine, has enrolled a total of 25 subjects in the SciStar study, plus 5 subjects from a previous Phase-1 safety trial. There are currently no approved therapies that improve the recovery of neurological function after suffering a severe SCI. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Stellar Biotechnologies, Inc. (NASDAQ: SBOT), which also belongs to the Healthcare sector as the Company Asterias Biotherapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=SBOT

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Asterias Biotherapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AST

About The SciStar Trial

The SciStar trial is an open-label, single-arm study to test three sequential escalating doses of AST-OPC1 administered at up to 20 million AST-OPC1 cells in patients with subacute motor complete (AIS-A or AIS-B) cervical (C-4 to C-7) SCI. The individuals in the trial had essentially lost all movement below the injury site and as a consequence, faced severe paralysis of the upper and lower limbs.

AIS-A patients have lost all motor and sensory functions of the body below the injury site, while AIS-B patients lost all motor functions, but may have retained some minimal sensory function below the injury site. AST-OPC1, according to Asterias, is being administered 21 to 42 days post the injury. Patients under the trial will be followed by neurological exams and imaging procedures to access the safety and the potential activity of the product.

About AST-OPC1

AST-OPC1 is an oligodendrocyte progenitor population, which was originally isolated in 1998, and is derived from human embryonic stem cells. The progenitor has been tested in vitro and in animals, where it had three potential reparative functions to address the complex pathologies originating at the site of a SCI. The activities of the progenitor from Asterias include production of neurotrophic factors, stimulation of vascularization, and induction of remyelination of denuded axons, which are critical for survival, regrowth, and conduction of nerve impulses through axons at the injury site.

Recently, in the Phase-1 clinical trial, five patients with SCI were administered two million AST-OPC1 cells at the injury site, 7 to 14 days after the injury. Owing to the successful end-results of the study, the Company received the US Food and Drug Administration (FDA) clearance to proceed with the testing of AST-OPC1 to patients with cervical spine injuries in the current SciStar study.

Future Prospects

According to the Company, severe SCIs can be devastating to the quality of life and the ability to function independently, without any aid. Lifetime healthcare and assistance costs over $5 million for these patients in the absence of any approved therapies to treat severe SCI. In October 2017, Asterias reported the 12-month data from the study’s Cohort-2 (AIS-A 10 million-cell cohort), including six subjects.

By 12 months, 67% of Cohort-2 subjects recovered 2 or more motor levels on at least one side, hence elevating the Company’s 12-month target of 45% – 50% of subjects achieving the threshold of improvement. The Company intends to report a 6-month data from Cohort-3 (AIS-A 20 million-cell cohort) and Cohort-4 (AIS-B 10 million-cell cohort) in February 2018, and the 12-month data from Cohorts-3 and -4 in August 2018. Also, Asterias expects to report the six-month top-line readout for the entire study in June 2018, and the 12-month top-line readout for the entire study in December 2018.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, Asterias Biotherapeutics’ stock dropped 2.27%, ending the trading session at $2.15.

Volume traded for the day: 113.10 thousand shares.

After yesterday’s close, Asterias Biotherapeutics’ market cap was at $121.93 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484755

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free earnings report on The Scotts Miracle-Gro Co. (NYSE: SMG). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SMG . The Company posted its financial results on November 07, 2017, for the fourth quarter fiscal 2017. The marketer of branded consumer lawn and garden products saw revenue and adjusted EPS surpassed analysts’ expectations. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, The Scotts Miracle-Gro most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=SMG

Earnings Highlights and Summary

For three months ended September 30, 2017, Scotts Miracle-Gro’s net revenues increased 8% to $376.7 million from $348.7 million in Q4 FY16. The Company’s net revenue surpassed analysts’ expectations of $371.6 million.

During FY17, the Company’s net revenues increased 5% to $2.64 billion from $2.51 billion in FY16.

For the reported quarter, Scotts Miracle-Gro’s gross profit decreased 4% to $88.1 million from $92.2 million in Q4 FY16. For the reported quarter, the Company’s gross margin decreased 300 basis points to 23.4% of revenue from 26.4% of revenue in Q4 FY16. For the reported quarter, the Company’s adjusted gross margin decreased 320 basis points to 23.4% of revenue from 26.6% of revenue in Q4 FY16.

During FY17, the Company’s gross profit increased 8% to $972.6 million from $900.3 million in FY16. During FY17, the Company’s gross margin increased 90 basis points to 36.8% of revenue from 35.9% of revenue in FY16.

For the reported quarter, Scotts Miracle-Gro’s adjusted EBITDA decreased 2% to $5.5 million from $5.6 million in Q4 FY16. For Q4 FY17, the Company’s adjusted EBITDA margin decreased 10 basis points to 1.5% of revenue from 1.6% of revenue in Q4 FY16.

For the reported quarter, Scotts Miracle-Gro’s operating loss was $26.1 million compared to operating loss of $17.2 million in Q4 FY16.

During Q4 FY17, Scotts Miracle-Gro’s EBT was negative $56.0 million compared to negative $18.7 million in Q4 FY16.

For the reported quarter, Scotts Miracle-Gro’s net loss was $42.3 million compared to net loss of $11.3 million in Q4 FY16. During Q4 FY17, the Company’s diluted EPS was negative $0.72 compared to negative $0.18 in the same period last year. For the reported quarter, Scotts Miracle-Gro’s adjusted net loss was $14.9 million compared to adjusted net loss of $12.4 million in Q4 FY16. During Q4 FY17, the Company’s adjusted diluted EPS was negative $0.26 compared to negative $0.20 in the same period last year. Adjusted diluted EPS surpassed analysts’ expectations of negative $0.29.

During FY17, the Company’s net income decreased 19% to $198.3 million from $246.1 million in FY16. During FY17, the Company’s diluted EPS decreased 17% to $3.29 from $3.98 in FY16.

Segment Details

US Consumer – During Q4 FY17, the Company’s US Consumer segment’s net revenue decreased 7% to $258.1 million from $278.9 million in the same period last year. The decrease was due to lower sales in the mass retail channel. For the reported quarter, the segment’s profit was negative $0.3 million compared to positive $11.2 million in Q4 FY16.

Hawthorne – During Q4 FY17, the Hawthorne segment’s net revenue increased 97% to $92.0 million from $46.8 million in the same period last year. For the reported quarter, the segment’s profit increased 73% to $9.0 million from $5.2 million in Q4 FY16.

Other – During Q4 FY17, the Other segment’s net revenue increased 16% to $26.6 million from $23.0 million in the same period last year. For the reported quarter, the segment’s profit was negative $0.9 million compared to negative $2.1 million in Q4 FY16.

Balance Sheet

As on September 30, 2017, Scotts Miracle-Gro’s cash and cash equivalents increased 321.3% to $120.5 million from $28.6 million on September 30, 2016. For the reported quarter, the Company’s long-term debt increased 22% to $1.26 billion from $1.03 billion in Q4 FY16.

For the reported quarter, the Company’s net accounts receivables decreased 5% to $286.6 million from $301.7 million in Q4 FY16. For the reported quarter, the Company’s accounts payable increased 16.7% to $153.1 million from $131.2 million in Q4 FY16.

During FY17, the Company’s net cash provided by operating activities increased 49.1% to $354.0 million from $237.4 million in FY16. During FY17, the Company’s free cash flow increased 58.8% to $284.4 million from $179.1 million in FY16.

During FY17, the Company’s free cash flow productivity was 130% compared to 56.9% in FY16.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, Scotts Miracle-Gro’s stock was marginally down 0.13%, ending the trading session at $102.85.

Volume traded for the day: 383.28 thousand shares, which was above the 3-month average volume of 321.10 thousand shares.

Stock performance in the last month – up 4.90%; previous three-month period – up 6.23%; past twelve-month period – up 8.09%; and year-to-date – up 7.64%

After yesterday’s close, Scotts Miracle-Gro’s market cap was at $5.89 billion.

Price to Earnings (P/E) ratio was at 31.67.

The stock has a dividend yield of 2.06%.

The stock is part of the Basic Materials sector, categorized under the Agricultural Chemicals industry. This sector was up 1.0% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484748

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free earnings report on TopBuild Corp. (NYSE: BLD). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BLD . TopBuild posted its third quarter fiscal 2017 (Q3 FY17) results on November 07, 2017. The leading installer and distributor of insulation product’s revenues grew 7.93%. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, TopBuild most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BLD

Earnings Highlights and Summary

During Q3 FY17, TopBuild’s revenues reflected growth of 7.93% to $489.04 million compared to $453.10 million in Q3 FY16. The Company’s revenue numbers fell short of analysts’ estimates of $491.43 million.

The Company had a gross profit of $120.84 million in Q3 FY17 compared to $108.14 million in Q3 FY16, increasing by 11.74% on a y-o-y basis. The Company’s gross margins expanded 80 basis points to 24.70% in the reported quarter.

TopBuild had an operating profit of $49.56 million in Q3 FY17 compared to $39.10 million in Q3 FY16, reflecting growth of 26.75%. The Company’s operating margin was 10.10% and the adjusted operating margin was 10.30% in the reported quarter. TopBuild’s adjusted EBITDA grew 28.90% to $57.60 million in the reported quarter compared to $44.60 million in Q3 FY16. The Company’s incremental EBITDA margin was 74.20% in Q3 FY17.

TopBuild’s net income advanced 27.79% to $31.39 million in Q3 FY17 compared to $24.57 million in Q3 FY16. The Company’s diluted earnings (EPS) was $0.88 per share in the reported quarter compared to $0.65 per share in Q3 FY16, reflecting growth of 35.38%. The Company’s earnings, adjusted for non-recurring gains for Q3 FY17, were $0.83 per share compared to $0.63 per share in Q3 FY16, beating analysts’ estimates of $0.82 per share.

TopBuild’s Segment Details

TopBuild has two business segments, namely:(i) Installation segment and (ii) Distribution segment.

Sales for the Installation segment were $333.24 million in Q3 FY17 compared to $300.01 million in Q3 FY16, increasing by 11.08% on a y-o-y basis. This segment’s operating profit was $41.00 million in the reported quarter compared to $32.31 million in Q3 FY16, advancing 26.89%.

The Distribution segment had revenues of $181.15 million in Q3 FY17 compared to $174.12 million in Q3 FY16, reflecting growth of 4.03%. The segment’s operating profit was $18.31 million in the reported quarter compared to $15.54 million in Q3 FY16, advancing 17.82%.

Cash Matters

TopBuild reported cash and cash equivalents of $18.46 million on September 30, 2017, compared to $104.50 million on September 30, 2016. The net inflow from operating activities was $54.62 million for nine months ending September 30, 2017, compared to $27.934 for the same period ending September 30, 2016.

During Q3 FY17, the Company made a payment of $100.00 million to Bank of America, Merrill Lynch, using $30.00 million of cash on hand and borrowing $70.00 million under its revolving facility, and in exchange received 1.50 million shares with a value of approximately $80.00 million. On a year-to-date basis, TopBuild has completed six acquisitions, which are expected to generate approximately $38.00 million of incremental revenues on an accrual basis. The Company had a total liquidity of $316.40 million and capital expenditures of $13.09 million on September 30, 2017.

Outlook

For fiscal 2017, TopBuild expects revenues in the range of $1.89 billion to $1.91 billion and adjusted EBITDA in the band of $190.00 million to $195.00 million.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, TopBuild’s stock advanced 2.84%, ending the trading session at $73.54.

Volume traded for the day: 196.08 thousand shares.

Stock performance in the last month – up 14.30%; previous three-month period – up 19.87%; past twelve-month period – up 100.38%; and year-to-date – up 106.57%

After yesterday’s close, TopBuild’s market cap was at $2.63 billion.

Price to Earnings (P/E) ratio was at 36.24.

The stock is part of the Industrial Goods sector, categorized under the General Building Materials industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484749